Project Grant R44AG062021

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Jillion Therapeutics Inc. aims to identify small molecule compounds that can bind to and modify the biological behavior of tau protein, which is implicated in Alzheimer's disease and other neurodegenerative "tauopathies". The $496,373 award, spanning September 2024 to August 2025, will utilize the company's DNA-encoded library (DEL) drug discovery platform to screen a large chemical...

This $999,822 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to Aeton Therapeutics Inc. supports the development of an anti-tau monoclonal antibody treatment for Alzheimer's disease. The key objectives are to: Evaluate the effectiveness of Aeton's lead candidate, AT-01, in treating neural cells and organoids in vitro compared to another anti-tau antibody, HJ8.7. Determine the efficacy and safety of AT-01 versus HJ8.7 in a mouse model of tauopathy, while...

This $4,618,216 Cooperative Agreement (U01AG088051) awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of CNDR-51997, a novel microtubule-stabilizing drug candidate for the treatment of Alzheimer's disease (AD) and related neurodegenerative tauopathies. The primary objectives are to advance CNDR-51997 through IND-enabling studies and submit an Investigational New Drug (IND) application to the FDA. This late-stage research builds on prior NIH-funded...

This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...

This Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, will fund the development of a Tau Progression Index (TPI) - a multimodal prognostic score to predict tau accumulation, neurodegeneration, and cognitive/functional decline in Alzheimer's disease (AD). The $2,500,027 award to Weill Medical College of Cornell University will recruit 130 non-demented participants with evidence of amyloid-beta and tau pathologies to undergo advanced MRI, PET, and...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $5,026,306 to Allyx Therapeutics Inc. to clinically evaluate the metabolism and efficacy of the novel compound BMS-984923 for the treatment of Alzheimer's disease (AD). The project aims to develop this disease-modifying drug by targeting the underlying mechanism of synapse loss, which is tightly correlated with cognitive decline in AD. Preliminary studies in preclinical mouse models have...

This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...

The U.S. National Institute on Aging (NIA) awarded a $2,217,438 Cooperative Agreement under the Aging Research program (CFDA 93.866) to Trustees of Indiana University (IU Indianapolis) to optimize SHIP1 inhibitors for the treatment of Alzheimer's disease. IU Indianapolis will collaborate with Purdue University and Indiana Biosciences Research Institute on this multi-year project. The key products and services to be delivered under this Cooperative Agreement include: Optimizing the potency and...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,012,534 to Eydis Bio, Inc. to develop orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's disease. The Phase I STTR grant supports identifying suitable TAK1 inhibitors with optimal central nervous system blood-brain barrier penetrance that can be further advanced into in vivo testing in the PS19 mouse model. The goal is to...